Status:
TERMINATED
Study of Epratuzumab in Systemic Lupus Erythematosus (SLE)
Lead Sponsor:
UCB Pharma
Conditions:
Systemic Lupus Erythematosus
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to evaluate the safety and efficacy of Epratuzumab with standard treatments for patients with SLE.
Eligibility Criteria
Inclusion
- +ANA at screening
- BILAG Index B Level Activity in at least 2 body systems/organs
- Has SLE by ACR revised criteria (meets,\<4 criteria)
Exclusion
- Active Severe Lupus as defined by BILAG Index Level A in any body system or organ.
- Allergy to human antibodies or Murine.
Key Trial Info
Start Date :
May 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2007
Estimated Enrollment :
54 Patients enrolled
Trial Details
Trial ID
NCT00383214
Start Date
May 1 2005
End Date
March 1 2007
Last Update
June 7 2012
Active Locations (60)
Enter a location and click search to find clinical trials sorted by distance.
1
Birmingham, Alabama, United States
2
Tucson, Arizona, United States
3
Los Angeles, California, United States
4
Upland, California, United States